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Abstract
Background: Although number of elderly patients with metastatic colorectal cancer (mCRC) is rapidly increasing,
this population is often underrepresented in clinical trials. Recently, a phase II trial demonstrated that capecitabine
and oxaliplatin (XELOX) combined with bevacizumab XELOX plus bevacizumab was effective and well tolerated by
elderly patients with mCRC who reside in Western countries. The aim of this study was to evaluate the safety and
efficacy of XELOX plus bevacizumab for Japanese patients aged ≥75 years with mCRC.
Methods: This prospective, open-label phase II trial recruited patients aged ≥75 years with previously untreated
mCRC between March 2010 and January 2012. Treatment consisted of 7.5 mg/kg of intravenous bevacizumab and
130 mg/m2 of oxaliplatin on day 1 of each cycle combined with 2000 mg/m2 of oral capecitabine per day on days
1–14 of each cycle. Treatment was repeated every 3 weeks until disease progression or termination of the study.
The primary endpoint was progression-free survival; the secondary endpoints were toxicity, overall response rate,
time-to-treatment failure, and overall survival.
Results: Thirty-six patients (male 58 %; median age 78 years; colon cancer 67 %) met all eligibility criteria and
received at least one course of the planned treatment. The median time-to-treatment failure was 7.0 months.
Twelve patients (33.3 %) experienced adverse effects (AEs) ≥ grade 3 and frequent AEs ≥ grade 3, including
neutropenia (22.2 %) and neuropathy (13.9 %). Hypertension was the most frequent AE ≥ grade 3 associated with
bevacizumab (11.1 %). Low baseline creatinine clearance associated significantly with the incidence of AEs ≥ grade
3. Response and disease control rates were 55.6 and 91.7 %, respectively. Median progression-free and overall
survival times were 11.7 months (95 % confidence interval, 8.0–13.4 months) and 22.9 months, respectively.
Conclusion: XELOX combined with bevacizumab was well tolerated by selected Japanese patients aged ≥75 years
with mCRC patients, and controlled clinical trials are now required to determine the survival benefit.
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Background
Colorectal cancer ranks worldwide as the third and
fourth most common cancer in women and men, re-
spectively, and the median survival of patients with
metastatic colorectal cancer (mCRC) treated with best
supportive care is approximately 6 months [1–3]. Treat-
ment outcomes are improved considerably by newly
developed chemotherapeutic agents and regimens. For
example, treatment using 5-fluorouracil (5-FU) plus iri-
notecan, oxaliplatin, or both combined with targeted
agents extends median overall survival (OS) to approxi-
mately 30 months [4, 5]. Current guidelines recommend
that first-line treatment for patients with mCRC should
include doublet chemotherapy plus a targeted agent, if
tolerated [6].
The prodrug capecitabine is activated by a unique
mechanism that exploits the high activity of thymidine
phosphorylase in malignant tissue that generates 5-FU
preferentially in tumor tissue [7]. Capecitabine under-
goes a three-step enzymatic conversion, and the final
stage is catalyzed by thymidine phosphorylase, which is
significantly more active in tumor tissue compared with
healthy tissue [7, 8]. Oral delivery of capecitabine simpli-
fies chemotherapy and provides convenient outpatient
therapy, because it avoids the complications and discom-
fort associated with intravenous administration and per-
mits prompt discontinuation of treatment when toxicity
occurs [9].
Combining capecitabine with oxaliplatin (XELOX) is
advantageous for the reasons as follows: synergistic ef-
fects, no overlapping toxicities, easy to administer, and
outpatient management [10–13]. Randomized phase III
trials demonstrate that outcomes using first-line XELOX
are comparable with those achieved using continuous
infusion of 5-FU and folinic acid combined with oxa-
liplatin (FOLFOX) [14, 15]. Moreover, combined with
bevacizumab, a recombinant humanized version of a
mouse monoclonal antibody against human vascular
endothelial growth factor, XELOX achieves significantly
improved progression-free survival (PFS) compared with
chemotherapy alone [16–18].
The average age of the population is steadily increas-
ing in many developed countries, particularly because of
improvements in public health, nutrition, disease pre-
vention, early detection, and continued progress in med-
ical research [19]. The increase in patients’ ages presents
the medical community with new challenges. For ex-
ample, more than 30 % of patients with newly diagnosed
CRC are aged at least 75 years [20]. Since the progres-
sive reduction of functional reserve that occurs in vari-
ous organs with ageing might increase the susceptibility
of the elderly to adverse effects, clinical trials for elderly
patients with mCRC have been conducted and tolerability
of UFT/leucovorin, XELOX, capecitabine plus bevacizumab
and S-1 plus bevacizumab were evaluated [21–26]. Yet, the
safety and efficacy of XELOX plus bevacizumab for elderly
patients remains to be determined because earlier large
clinical trials limited eligibility to individuals <70 or 75 years
owing to frail health [16, 17, 27]. Recently, a phase II
trial (BECOX study) found that XELOX combined
with bevacizumab is effective and well tolerated by
patients aged ≥70 years with mCRC who reside in
Spain [28]. However, insufficient evidence is available
to establish the safety and benefit of XELOX plus
bevacizumab for Japanese patients with mCRC included
in this age group. Moreover, lack of robust evidence of the
new treatment described above may subject patients of
advanced age to more conservative and less effective
treatments. For example, older patients are more likely
to receive monotherapy instead of combination ther-
apy that does not include agents that target specific
molecules [29–31].
Therefore, the aim of the present study was to evaluate
the feasibility of XELOX plus bevacizumab for selected
Japanese patients with mCRC aged ≥75 years.
Methods
Patients and methods
A single-arm multicenter phase II trial (ASCA trial,
Avastin plus XELOX Strategy for elderly patients with
metastatic colorectal cancer) was planned to evaluate
the safety and efficacy of XELOX plus bevacizumab for
patients with mCRC ≥75 years of age [32]. The scientific
and ethical validity of the study protocol was reviewed
and approved by an internal review board of each
participating facility (the Institutional Review Board at
Osaka National Hospital, Osaka City General hospital,
Osaka Rosai Hospital, Kitakyushu General Hospital,
Kinki University, Kochi University, Fukui-ken Saiseikai
Hospital, Saitama Medical Center, Jichi Medical University,
Izumisano Municipal Hospital, Sakai City Hospital,
Toyonaka Municipal Hospital, Dongo Hospital, Nara
Social Insurance Hospital, Hakodate Goryoukaku Hospital,
Fukuiken Saiseikai Hospital, Minoh City Hospital and
Mimihara General Hopital). Written informed consent
was obtained from all patients before enrollment. This
study was conducted in accordance with the Declaration
of Helsinki (2008) and registered with the University Hos-
pital Medical Information Network (UMIN) Clinical Trial
Registry as UMIN000003500 (http://www.umin.ac.jp/ctr/
index.htm).
Patients from 18 institutes were included in this study
if they met all eligibility criteria as follows: (1) written
informed consent before treatment; (2) age ≥75 years
when informed consent was granted; (3) Eastern Co-
operative Oncology Group (ECOG) Performance Status
(PS) of 0 or 1; (4) life expectancy >3 months; (5) histologi-
cally confirmed colorectal adenocarcinoma; (6) measurable
Munemoto et al. BMC Cancer  (2015) 15:786 Page 2 of 10
disease consistent with the Response Evaluation Criteria in
Solid Tumors (RECIST) version 1.1; (7) no prior chemo-
therapy (adjuvant chemotherapy included fluorouracil
and/or oxaliplatin was allowed, but the last course of
adjuvant chemotherapy must have concluded more
than six months prior to colorectal cancer recurrence); (8)
adequate function of vital organs, including liver and
kidney (total bilirubin ≤1.5-times the institutional upper
normal limit, aspartate aminotransferase and alanine ami-
notransferase ≤2.5-times the institutional upper normal
limit, and serum creatinine ≤ institutional upper normal
limit or creatinine clearance (CCr, calculated using the
Cockcroft–Gault formula) ≥50 ml/min); adequate bone
marrow function (leucocyte count ≥3000/mm3, neutrophil
count ≥1500/mm3, platelet count ≥100,000/mm3, and
hemoglobin ≥9.0 g/dl).
Key exclusion criteria included uncontrolled pleural
effusion or ascites, brain metastasis, presence of other
active malignancies, present or past (within the past
1 year) clinically significant cerebrovascular disease or
thromboembolism, surgery planned during the course of
the trial, anticoagulant treatment, coagulation disorder,
nephropathy requiring medication or transfusion, uncon-
trolled hypertension or diabetes mellitus, uncontrolled
diarrhea, history of bevacizumab treatment, and inability
to take drugs orally [32].
Treatment
Treatment consisted of intravenous administration of
7.5 mg/kg of bevacizumab and 130 mg/m2 of oxaliplatin
on day 1 of each cycle combined with 2000 mg/m2 oral
capecitabine per day on days 1–14 of each cycle [32].
The end of the protocol treatment period was not
prescribed. Treatment was repeated every 3 weeks until
disease progression or termination of the study. The
study protocol had no provisions regarding the second-
line treatment. When patients exhibited adverse effects
(AEs), the dose of each drug was reduced as specified in
the study protocol that provided detailed algorithms to
manage drug-specific toxicities such as oxaliplatin-related
neuropathy, capecitabine-related diarrhea, hand–foot syn-
drome, bevacizumab-related hypertension, bleeding, and
thromboembolism as well as other treatment-related tox-
icities. The dose reduction or stopping criteria of drugs
due to adverse events is defined based on the haemato-
logical toxicity (Grade 4 neutropenia, Grade 3 febrile neu-
tropeni a or Grade 3 or more decrease in platelets) and
Grade 3 non-haematological toxicity. Dose reduction due
to adverse events was performed for each drug as specified
in the study protocol, which provided detailed algo-
rithms to manage drug-specific toxicities such as
oxaliplatin-related neuropathy as follows; G1, continue
administration; G2/3, until recovery to G1 or less and
resume oxaliplatin with the reduction dose (for the
first time 100 mg/m2, for the second time 85 mg/m2);
G4, discontinuation of oxaliplatin.
Study parameters
Screening and baseline evaluations included assessing
ECOG PS and conducting blood tests and physical ex-
aminations. Baseline tumor status with prospective iden-
tification of index lesions that were followed over the
course of the study, was assessed using computed tom-
ography (CT) studies of the chest, abdominal, and pelvis
as well as determination of serum tumor-marker levels
(carcinoembryonic antigen and carbohydrate antigen
19–9). During treatment, tumor status was assessed at
the completion of each 8-week cycle. RECIST ver. 1.1
was used to evaluate responses and determine disease
progression. Response rate assessment was done locally.
Toxicities, graded according to the criteria of the National
Cancer Institute Common Terminology for Adverse
Events (version 4.0), were evaluated during the study
period and for 28 days after the last dose administered
during the study by conducting physical examinations and
laboratory tests (hematology, chemistry and electrolytes,
and urinalysis), and evaluating ECOG PS. Patients who
discontinued the protocol treatment were followed every
2 months until death or loss to follow-up. Neurotoxicity
was graded as follows: G1 (asymptomatic) loss of deep
tendon reflexes or paresthesia, G2 (moderate symptoms)
limiting instrumental activities of daily living, G3 (severe
symptoms) limiting daily self-care activities; G4 (life-
threatening consequences) urgent intervention indicated,
and G5 (death). Patients were questioned about their use
of concomitant medication and AEs. Association between
the incidence of AEs ≥G3 and baseline CCr, American
Society of Anesthesiologists (ASA) score (comorbidity
index), ASA Physical Status Classification System score,
age, body mass index (BMI), and sex were evaluated as
potential risk factors for severe AEs.
Statistical analysis
The primary objective of the ASCA study was to deter-
mine PFS. Secondary endpoints were toxicity, overall re-
sponse rate, time to treatment failure (TTF), and OS.
Assuming a threshold PFS of 6.5 months and an esti-
mated median PFS of 10.5 months, and referring to data
from previous clinical trials we determined that a signifi-
cance level = 95 %, an α-error = 0.05, and 32 patients
were required. Estimating a loss as high as 10 % of the
final subject population, 35 patients were required. The
Kaplan–Meier method was used to estimate survival,
and the Cox proportional hazards model was used to
calculate confidence intervals (CI). PFS was defined as
the interval from the time of enrolment to the date of
the first documented disease progression or a patient’s
death from any cause. OS was defined as the date of
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enrolment until the date of death from any cause. TTF
was defined as the time from randomization to discon-
tinuing treatment for any reason, including disease pro-
gression, treatment toxicity, patient preference, or death.
The goodness-of-fit for AEs ≥ grade 3 was assessed by
calculating the area under the curve (AUC), and optimal
cutoff values were determined using the Youden index.
The χ2 test was used to compare the difference between
the values of two patient groups. A statistically signifi-
cant difference was defined as P < 0.05.
Results
Patient characteristics
Thirty-seven patients treated between March 2010 and
January 2012 at 18 institutes were screened and met all
eligibility requirements. One patient withdrew from the
study before receiving treatment. The 36 patients (male
58 %; median age 78 years; colon cancer 67 %) enrolled
received at least one course of the planned treatment.
Baseline patient characteristics are shown in Table 1.
Safety and response to treatment
Patients were treated with a median of five cycles of
XELOX plus bevacizumab (range 1–17), and the median
relative dose intensities during the initial protocol
(XELOX plus bevacizumab) were 86, 89, and 100 % for
capecitabine, oxaliplatin, and bevacizumab, respectively.
There were 14 patients who continued to receive the
protocol treatment after withdrawal of oxaliplatin (cape-
citabine with bevacizumab for 12 and capecitabine alone
for two patients). The median TTF was 7.0 months
(95 % CI 4.7–10.8 months) (Fig. 1a). The reasons for dis-
continuing treatment were disease progression (n = 14),
AEs (n = 14), withdrawal (n = 6), and surgery for metas-
tases (n = 2). AEs that prevented continuing were as
follows: neutropenia (n = 3), thrombotic disease (n = 2),
anorexia (n = 2), ileus (n = 2), heart failure (n =1), hand–
foot syndrome (n = 1), cerebral bleeding (n = 1), neur-
opathy (n = 1), and fatigue (n = 1).
Treatment-related toxicities are listed in Table 2.
Thirty-four (94.4 %), and 12 (33.3 %) patients experi-
enced AEs or AEs ≥ grade 3, respectively, and one
treatment-related death was caused by intracranial bleed-
ing. The latter patient was a 77-year-old woman with liver
and lung metastasis without serious comorbidities who
received seven courses of protocol treatment (XELOX
plus bevacizumab) using the regular dose. During the
eighth course, she lost consciousness, was diagnosed with
intracerebral bleeding according to the results of a CT
scan, and chemotherapy was discontinued. Frequent ad-
verse events (any grade) were as follows: neuropathy
(83.3 %), anemia (80.5 %), thrombocytopenia (58.3 %),
hand–foot syndrome (58.3 %), and neutropenia (55.6 %).
Frequent AEs ≥ grade 3 were neutropenia (22.2 %) and
neuropathy (13.9 %). Bevacizumab-related AEs, protein-
uria (36.1 %), and hypertension (27.8 %), were frequently
observed for all grades, and the most frequent ≥ grade-3
event was hypertension (11.1 %).
We evaluated the association between AEs ≥G3 and
baseline patient conditions including CCr, comorbidity
index, ASA Physical Status Classification System score,
age, BMI, and sex. These findings identified baseline
CCr as a potential predictor of AEs ≥ grade 3. The AUC
value of baseline CCr = 0.69, and the optimal cutoff
value for predicting AEs ≥ grade 3 = 64 ml/min (sensitiv-
ity = 0.91, specificity = 0.50 (Additional file 1: Figure S1a).
Further, patients with baseline CCr <64 ml/min had a
Table 1 Baseline patient characteristics (n = 36)














Not performed 13 (36.1)
Adjuvant chemotherapy
Performed 9 (25.0)







Lymph nodes 14 (38.9)
Peritoneum 2 (5.6)
Other 2 (5.6)





Median (range) 60.8 (32.6–84.6)
ECOG Eastern Cooperative Oncology Group
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significantly higher incidence of AEs ≥G3 compared with
those with baseline CCr ≥64 ml/min (77.8 % and 22.2 %,
respectively, P = 0.018). No association was found between
evaluated factors other than CCr (comorbidity index, ASA
Physical Status Classification System score, age, BMI, and
sex) and incidence of AEs ≥G3.
Efficacy
The best radiographic response of each patient is pre-
sented in Additional file 1: Figure S1b. Responses to
treatment were defined as follows: complete response
(CR), partial response (PR), stable disease (SD), and
progressive disease, according to the RECIST ver. 1.1
definitions. The rates for CR, PR, and SD were 2.8, 52.8,
and 36.1 %, respectively, and the response and disease
control rates were 55.6 and 91.7 %, respectively (Table 3).
The median PFS was 11.7 months (95 % CI, 8.0–
13.4 months (Fig. 1b), and the median OS was 22.9 months
(95 % CI 17.6–33.0 months, Fig. 1c).
Discussion
Robust evidence from the TREE 1 (XELOX) and TREE 2
(XELOX plus bevacizumab) (TREE1/2) randomized clin-
ical trials shows that XELOX combined with bevacizu-
mab offers survival benefits to patients with mCRC [33].
Unfortunately, insufficient evidence is available to insure
the safety and benefits of combined treatment with
XELOX and bevacizumab for patients aged ≥75 years,
that were often excluded from randomized trials, al-
legedly because of frail health or because they repre-
sented a minority of enrolled patients [16–18]. Feliu et
al. conducted a recent phase II trial (BECOX study) in
Spain and demonstrated that XELOX plus bevacizumab
was effective and well tolerated by patients with mCRC
aged ≥70 years [28]. Here we designed a multicenter
open-label phase II trial to evaluate the safety and effi-
cacy of XELOX plus bevacizumab for Japanese patients
aged ≥75 years with mCRC. The doses of capecitabine,
oxaliplatin, and bevacizumab were determined with ref-
erence to the TREE1/2 trials [33], although the median
age of patients enrolled in these studies was 62 years.
In the present study, we administered a median of five
cycles of treatment (XELOX plus bevacizumab) (range,
1–17). Relative dose-intensities of capecitabine, oxalipla-
tin, and bevacizumab during the initial protocol (XELOX
plus bevacizumab) were 86, 89, and 100 %, respectively.
The median TTF was 7.0 months, although TTF repre-
sents a composite endpoint influenced by factors unre-
lated to efficacy, because discontinuation may be due to
toxicity, patient preference, or a physician's reluctance to
continue therapy. These results are similar to, or some-
what better compared with those of the TREE1/2 trials
as well as those of the BECOX study [28, 33], despite
the older patients studied here. The results of the
present study and relevant clinical trials for mCRC were
summarized in Table 4. Because therapeutic regimens
with or without bevacizumab do not necessarily affect rela-
tive dose intensities of capecitabine and oxaliplatin, our
results are comparable with the results of trials involving
younger patients indicating that XELOX plus bevacizumab
is well tolerated by patients aged ≥75 years with mCRC.
The overall frequency of grade 3/4 AEs, including
hematologic and nonhematologic events, is generally
consistent with those of the TREE 1/2 trials, an earlier
phase I/II trial conducted in Japan and the BECOX study
conducted in Spain [28, 33, 34]. The most characteristic
finding here was that the incidence of grade-1 neuropathy
Fig. 1 The Kaplan–Meier curves for TTF, PFS, and OS. a The median
time to treatment failure was 7.0 months (95 % CI 4.7–10.8 months).
b The median progression-free survival time was 11.7 months (95 % CI
8.0–13.4 months). c The median overall survival time was 22.9 months
(95 % CI 17.6–33.0 months)
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reached 83.3 %, and that of grades-3/4 neuropathy was
13.9 %. Cumulative neuropathy represents one of the
major problems related to long-term therapy using
oxaliplatin-containing regimens for patients with mCRC,
which is the main driver for trying to limit the dose of
oxaliplatin [12, 14, 28]. The frequency (13.9 %) of G3/4
neuropathy encountered here was higher compared with
those reported by earlier studies of Western cohorts
(Table 4), although dose reduction and discontinuation of
oxaliplatin was strictly defined in the study protocol
[13, 28, 35]. A pilot study evaluating the safety of
XELOX plus bevacizumab conducted in Japan reported a
17 % frequency of neuropathy G3/4 17 %, indicating that
the frequency of severe neuropathy induced by XELOX
plus bevacizumab differs between Western and Japanese
patients [34]. Haller et al. showed the regional differences
in tolerability of XELOX between the United States, East
Asia, and the rest of the world [36]. Japanese patients
experienced fewer G3/4 AEs during XELOX treatment
compared with those from other regions, but no detailed
data for neuropathy was provided.
Further, there remains room for discussion about the
survival benefit of adding oxaliplatin. For example, in
the AVEX study that evaluated capecitabine plus bevaci-
zumab versus capecitabine alone in patients with mCRC
aged ≥70 years, the OS of those treated with capecita-
bine plus bevacizumab is similar OS to that our present
study (20.7 months) [22]. Further, the FOCUS2 trial that
compared capecitabine plus oxaliplatin with capecitabine
Table 2 Treatment-related adverse events
Grades 1/2 Grade 3 Grades 4/5 All grades (%) ≥Grade 3 (%)
Hematologic AEs
Overall 94.4 33.3
Leucopenia 14 1 0 41.7 2.8
Neutropenia 12 7 1 55.6 22.2
Anemia 27 2 0 80.5 5.6
Thrombocytopenia 19 2 0 58.3 5.6
Non-hematologic AEs
Elevated AST 11 0 0 30.5 0
Elevated ALT 6 0 0 16.7 0
Hyperbilirubinemia 2 0 0 5.6 0
Fatigue 7 3 0 27.8 8.3
Anorexia 9 2 0 27.8 5.6
Nausea 4 0 0 11.1 0
Vomiting 3 1 0 11.1 2.8
Diarrhea 4 2 0 16.7 5.6
Stomatitis 5 0 0 11.1 0
Hand–foot syndrome 18 3 0 58.3 8.3
Injection site reaction 3 0 0 8.3 0
Neuropathy (sensory) 25 5 0 83.3 13.9
Allergy 2 0 0 5.6 0
Bevacizumab-associated AEs
Hypertension 6 4 0 27.8 11.1
Proteinuria 11 2 0 36.1 5.6
Thrombosis 0 1 0 2.8 2.8
Bleeding 1 1 1 8.3 5.6
AE adverse effect
Table 3 Treatment profiles





Not evaluated 3 (8.3)
Response rate (CR + PR) 20 (55.6)
Disease control rate (CR + PR + SD) 33 (91.7)
CR complete response, PR partial response, SD stable disease, PD
progressive disease
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Table 4 Summary of our results and relevant clinical trials for mCRC
Study/first author Phase Treatment Country n ECOG PSa Age (median) RR PFS (month) OS (month) Neuropathy (G3/4) Ref
XELOX
Cassidy J 2 XELOX 6 European, Canada 96 0–1 34–79 (64) 55 % 7.7 19.5 17 % 12
TREE-1
Hochster HS






18 % vs 10 %
vs 21 %
33




3 IFL vs IFL + Bev United States, Australia,
New Zealand
813 0–1 18–(59) 35 % vs 45 % 6.2 vs 10.6 15.6 vs 20.3 - 17
E3200
Giantonio BJ













3 FOLFIRI + cetuximab vs
FOLFIRI + BEV
Germany, Austria 592 0–2 27–79 (65) 62 % vs 58 % 10.0 vs 10.3 28.7 vs 25.0 0.7 % vs 1.4 % 4
CALGB/SWOG
80405b
3 FOLFIRI or mFOLFOX6 + cetuximab
vs FOLFIRI or mFOLFOX6 + BEV
United States 1137 0–1 20–89 (59) - 10.5 vs 10.8 29.9 vs 29.0 12 % vs 14 % 5
XELOX + BEV
Wong NS 2 XELOX + BEV United States 50 0–2 24–81 (55) 50 % 10.3 23.3 14 % 11
TREE-2
Hochster HS
2 mFOLFOX6 + BEV vs FOL + BEV vs
XELOX + BEV











3 FOLFOX4/XELOX vs FOLFOX4/
XELOX + BEV




2 XELOX + BEV Japan 36 0.–1 75–86 (78) 56 % 11.7 22.9 13.9 % -
SGOSG-CR0501
Matsumoto T
2 UFT + LV Japan 21 0–2 75–83 (79) 33 % 5.3 18 0 % 21
Feliu J 2 Capecitabine + BEV Spain 59 0–2 73–79 (75) 34 % 10.8 18.0 0 % 24
Feliu J 2 XELOX Spain 54 0–2 70–82 (76) 36 % 5.8 13.2 2 % 25
BECOX
Feliu J
2 XELOX + BEV Spain 69 0–1 70–85 (75) 31 % 11.1 20.4 4 % 28
BASIC trial
Yoshida M
2 S-1 + BEV Japan 56 0–1 66–85 (75) 57 % 9.9 25.0 0 % 26
AVEX
Cunningham D
3 Capecitabine vs capecitabine +
BEV
Worldwide 280 0–2 70–87 (76) 10 % vs 19 % 5.1 vs 9.1 16.8 vs 20.7 0 % 22
FOCUS2
Seymour MT
3 FL vs OxFU vs Capecitabine vs
XELOX
United Kingdom 459 0–2 35–87 (74) 11 % vs 38 %
vs 14 % vs 32 %
3.5 vs 5.8
vs 5.2 vs 5.8
10.1 vs 10.7
vs 11.0 vs 12.4
0 % vs 1 % vs 0 %
vs 4 %
23
ECOG the Eastern Cooperative Oncology Group, PS performance status, RR response rate, PFS progression free survival, OS overall survival
aIn the eligibility criteria













alone, found no significant benefit of adding oxaliplatin
[23]. Considering the high prevalence of neuropathy
here, the benefit of adding oxaliplatin to capecitabine
combined with bevacizumab for older Japanese patients
with mCRC should be evaluated in clinical trials involving
a large number of patients.
During the present study, one patient died because of
treatment-related intracerebral bleeding. Although most
AEs associated with bevacizumab (hypertension, protein-
uria, and bleeding) are manageable, they infrequently lead
to death. The patient had normal blood-clotting function
as defined by the eligibility criteria, and the onset of
intracerebral bleeding occurred after seven cycles of the
protocol dose of XELOX plus bevacizumab. However, the
overall safety profile of XELOX combined with bevacizu-
mab for patients aged ≥75 years was similar to those of
previous clinical trials [27, 33]. From our experience, we
propose to monitor neurological signs on each visit and
perform cerebral imaging on low threshold in symptom-
atic patients. In the present study, the incidence of AEs
was independent of patients’ sex, age, and BMI. In con-
trast, low baseline CCr (<64 ml/min) was associated with
the frequency of severe AEs, suggesting that baseline CCr
should be considered as a determinant of the suitability of
treating older patients with XELOX plus bevacizumab.
However, further studies of a larger cohort are required.
Our trial achieved response and disease control rates
of 55.6 and 91.7 %, respectively. The primary endpoint,
median PFS, was 11.7 months (95 % CI 8.0–13.4 months),
and the median OS was 22.9 months (95 % CI 17.6–
33.0 months). The median PFS in the TREE 2 trial, the
earlier Japanese phase I/II trial, and the BECOX study
were 10.3, 11.0 and 11.1 months, respectively [21, 28, 33].
The median OS of patients was 22.9 months in our
present study, which is somewhat shorter compared with
large studies of younger populations. For example, an OS
of approximately 29 months was reported by the FIRE-3
and CALGB/SWOG 80405 trials [4, 5]. In contrast, an
earlier study of XELOX combined with bevacizumab for
Western patients with mCRC aged 75 years demonstrated
that OS was 20.4 months [28].
Folprecht et al. analyzed the differences in efficacy of
5-FU-based chemotherapy between age groups >70 years
and <70 years with mCRC, and concluded that elderly
patients benefit at least to the same extent from palliative
chemotherapy with 5-FU compared with younger patients
[37]. Recently, Lieu et al. analyzed the large database of the
ARCAD Clinical Trials Program and evaluated primary
age effects and interactions with sex and PS [38]. They
demonstrated that greater age was associated with poorer
OS and PFS among treated patients with mCRC independ-
ent of sex and PS [38]. The main reason for the survival
differences between our study and those of the FIRE-3 and
CALGB/SWOG 80405 trials might be accounted for by
the age of the patients rather than regional differences, and
our results can be considered to reveal a reasonable out-
come for patients aged ≥75 years [4, 5].
The present study included some limitations as follows.
The relatively small sample size precluded subgroup ana-
lysis of age, second-line treatment, and renal function. We
selected patients according to strict eligibility criteria to
ensure consistency with those of younger individuals.
Therefore, these criteria may not be applicable to routine
clinical practice. In addition, serial data were unavailable
for blood cholesterol, triglyceride, and glucose concentra-
tions that are influenced by capecitabine. The discussion
might be limited due to lack of data on RAS/BRAF status.
No elderly specific evaluation was conducted though the
comprehensive geriatric assessment would have been of
high value to learn about factors that are specific to the
older patient population which could affect treatment
outcome. Because the study protocol had no provi-
sions regarding the second-line treatment, the detailed
information of second-line treatment is unavailable. We
were unable to determine the survival benefit of XELOX
plus bevacizumab because this was a single-arm study.
Conclusions
Our results indicate that XELOX combined with bevaci-
zumab was well tolerated by selected Japanese patients
aged ≥75 years with mCRC. Therefore, XELOX plus
bevacizumab should not be withheld from these patients
because of age alone. The survival benefit of this regimen
must be determined by further controlled clinical trials.
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and waterfall plot. (a) Receiver operating characteristic curve for baseline
CCr as a predictor of AEs ≥ grade 3. The AUC and optimal cutoff values
were 0.69 and 64 ml/min, respectively. (b) Waterfall plot of maximum
percentage tumor shrinkage. Progressive disease was not detected, and
lesions with shrinkage of ≥30 % were present in 20 patients
(55.6 %). (TIFF 6032 kb)
Abbreviations
mCRC: Metastatic colorectal cancer; 5-FU: 5-fluorouracil; OS: Overall survival;
XELOX: Capecitabine and oxaliplatin; FOLFOX: Fluorouracil, folinic acid and
oxaliplatin; PFS: Progression-free survival; UMIN: University Hospital Medical
Information Network; ECOG: Eastern Cooperative Oncology Group;
PS: Performance status; RECIST: Response evaluation criteria in solid tumors;
CCr: Creatinine clearance; AE: Adverse effect; CT: Computed tomography;
ASA: American Society of Anesthesiologist; BMI: Body mass index; TTF: Time
to treatment failure; CI: Confidence interval; AUC: Area under the curve;
CR: Complete response; PR: Partial response; SD: Stable disease.
Competing interests
Keiichiro Ishibashi received lecture fees from Chugai Pharmaceutical Co., Ltd.,
Takeda Pharmaceutical Company Limited, Bayer Yakuhin, Ltd., Merck Serono
Co., Ltd., Taiho Pharmaceutical Co., Ltd., Astellas Pharma. Inc., and Mitsubishi
Tanabe Pharma Corporation. Junichi Sakamoto advises Takeda Pharmaceutical
Company Limited and received lecture fees from Tsumura Co., Ltd. Hideyuki
Mishima received lecture fees from Chugai Pharmaceutical Co., Ltd. and
research funding from Chugai Pharmaceutical Co., Ltd. and Yakult Co., Ltd.
Munemoto et al. BMC Cancer  (2015) 15:786 Page 8 of 10
Authors’ contributions
MY, IK, HT, KM, HJ, FM, TA, MY, and NM collected cases and clinical data.
MM, OT, and MH conceived and designed the study. OK conducted statistical
analyses. MK prepared the initial manuscript. JS supervised the project.
All authors contributed to the final manuscript and read and approved
the final manuscript.
Acknowledgements
This study was supported, in part, by the nonprofit organization
Epidemiological and Clinical Research Information Network (ECRIN).
Author details
1Department of Surgery, Fukuiken Saiseikai Hospital, Fukui, Japan.
2Department of Gastroenterological Surgery (Surgery II), Nagoya University
Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550,
Japan. 3Department of Digestive Tract and General Surgery, Saitama Medical
Center, Saitama Medical University, Kawagoe, Japan. 4Department of
Gastroenterological Surgery, Osaka University Graduate School of Medicine,
Osaka, Japan. 5Department of Human Health and Medical Sciences, Kochi
Medical School, Kohasu, Japan. 6Department of Surgery, Osaka Rosai Hospital,
Sakai, Japan. 7Department of Surgery, Hyogo Prefectural Nishinomiya
Hospital, Nishinomiya, Japan. 8Surgical Division, Hakodate Goryoukaku
Hospital, Hakodate, Japan. 9Department of Internal Medicine, Dongo
Hospital, Yamatotakada, Nara, Japan. 10Department of Surgery, Minoh City
Hospital Gastrointestinal Research Center, Minoh, Osaka, Japan. 11Department
of Surgical Oncology, Gifu University Graduate School of Medicine, Gifu,
Japan. 12Director, Tokai Central Hospital, Gifu, Japan. 13Matsuoka Clinic,
Kitakatsuragi, Nara, Japan. 14Department of Biostatistics, School of Public
Health, Tokyo University Graduate School of Medicine, Tokyo, Japan.
15Interfaculty Initiative in Information Studies, Tokyo University, Tokyo, Japan.
16Unit of Cancer Center, Aichi Medical University, Nagakute, Japan.
Received: 22 January 2015 Accepted: 8 October 2015
References
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer
statistics. CA Cancer J Clin. 2011;61:69–90.
2. Gruenberger B, Tamandl D, Schueller J, Scheithauer W, Zielinski C, Herbst F,
et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for
patients with potentially curable metastatic colorectal cancer. J Clin Oncol.
2008;26:1830–5.
3. Scheithauer W, Rosen H, Kornek GV, Sebesta C, Depisch D. Randomised
comparison of combination chemotherapy plus supportive care with
supportive care alone in patients with metastatic colorectal cancer. BMJ.
1993;306:752–5.
4. Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U,
Al-Batran SE, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab
as first-line treatment for patients with metastatic colorectal cancer (FIRE-3):
a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15:1065–75.
5. Venook AND, Lenz H, Innocenti F, Mahoney M, O'Neil B, Shaw J, et al.
CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI)
or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or
cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated
metastatic adenocarcinoma of the colon or rectum (MCRC). J Clin Oncol.
2014;32:5s.
6. Kirstein MM, Lange A, Prenzler A, Manns MP, Kubicka S, Vogel A. Targeted
therapies in metastatic colorectal cancer: a systematic review and
assessment of currently available data. Oncologist. 2014;19:1156–68.
7. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, et al. Design of a
novel oral fluoropyrimidine carbamate, capecitabine, which generates
5-fluorouracil selectively in tumours by enzymes concentrated in human
liver and cancer tissue. Eur J Cancer. 1998;34:1274–81.
8. Schuller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, et al.
Preferential activation of capecitabine in tumor following oral
administration to colorectal cancer patients. Cancer Chemother Pharmacol.
2000;45:291–7.
9. Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, et al.
First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable
safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol.
2002;13:566–75.
10. Borner MM, Dietrich D, Stupp R, Morant R, Honegger H, Wernli M, et al.
Phase II study of capecitabine and oxaliplatin in first- and second-line
treatment of advanced or metastatic colorectal cancer. J Clin Oncol.
2002;20:1759–66.
11. Wong NS, Fernando NH, Bendell JC, Morse MA, Blobe GC, Honeycutt W, et al.
A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose
bevacizumab in the treatment of metastatic colorectal cancer. Clin Colorectal
Cancer. 2011;10:210–6.
12. Cassidy J, Tabernero J, Twelves C, Brunet R, Butts C, Conroy T, et al. XELOX
(capecitabine plus oxaliplatin): active first-line therapy for patients with
metastatic colorectal cancer. J Clin Oncol. 2004;22:2084–91.
13. Makatsoris T, Kalofonos HP, Aravantinos G, Papadimitriou C, Kastritis E,
Rigatos SK, et al. A phase II study of capecitabine plus oxaliplatin (XELOX):
a new first-line option in metastatic colorectal cancer. Int J Gastrointest
Cancer. 2005;35:103–9.
14. Martoni AA, Pinto C, Di Fabio F, Lelli G, Rojas Llimpe FL, Gentile AL, et al.
Capecitabine plus oxaliplatin (xelox) versus protracted 5-fluorouracil venous
infusion plus oxaliplatin (pvifox) as first-line treatment in advanced
colorectal cancer: a GOAM phase II randomised study (FOCA trial). Eur J
Cancer. 2006;42:3161–8.
15. Ducreux M, Bennouna J, Hebbar M, Ychou M, Lledo G, Conroy T, et al.
Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus
oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal
cancer. Int J Cancer. 2011;128:682–90.
16. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S.
Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/
leucovorin improves survival for patients with metastatic colorectal cancer.
J Clin Oncol. 2005;23:3706–12.
17. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W,
et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for
metastatic colorectal cancer. N Engl J Med. 2004;350:2335–42.
18. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR,
et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and
leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer:
results from the Eastern Cooperative Oncology Group Study E3200. J Clin
Oncol. 2007;25:1539–44.
19. Groves R. National bibliography of US government publications. Statistical
Abstract of the United States: 2008–2011 Washington, DC: US Census
Bureau; 2011. 2011 http://www.census.gov/en.html
20. Gallego R, Sanchez N, Maurel J. Chemotherapy for elderly patients with
advanced colorectal carcinoma. Expert Rev Anticancer Ther. 2006;6:795–800.
21. Matsumoto T, Nishina T, Mizuta M, Tsuji A, Watanabe R, Takahashi I, et al.
Phase II study of first-line chemotherapy with uracil-tegafur plus oral
leucovorin in elderly (>/=75 years) Japanese patients with metastatic
colorectal cancer: SGOSG-CR0501 study. Int J Clin Oncol. 2014.
22. Cunningham D, Lang I, Marcuello E, Lorusso V, Ocvirk J, Shin DB, et al.
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients
with previously untreated metastatic colorectal cancer (AVEX): an open-label,
randomised phase 3 trial. Lancet Oncol. 2013;14:1077–85.
23. Seymour MT, Thompson LC, Wasan HS, Middleton G, Brewster AE, Shepherd
SF, et al. Chemotherapy options in elderly and frail patients with metastatic
colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial.
Lancet. 2011;377:1749–59.
24. Feliu J, Safont MJ, Salud A, Losa F, Garcia-Giron C, Bosch C, et al.
Capecitabine and bevacizumab as first-line treatment in elderly patients
with metastatic colorectal cancer. Br J Cancer. 2010;102:1468–73.
25. Feliu J, Salud A, Escudero P, Lopez-Gomez L, Bolanos M, Galan A, et al. XELOX
(capecitabine plus oxaliplatin) as first-line treatment for elderly patients over
70 years of age with advanced colorectal cancer. Br J Cancer. 2006;94:969–75.
26. Yoshida M, Muro K, Tsuji A, Hamamoto Y, Yoshino T, Yoshida K, et al.
Combination chemotherapy with bevacizumab and S-1 for elderly patients
with metastatic colorectal cancer (BASIC trial). Eur J Cancer. 2015;51:935–41.
27. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al.
Bevacizumab in combination with oxaliplatin-based chemotherapy as
first-line therapy in metastatic colorectal cancer: a randomized phase III
study. J Clin Oncol. 2008;26:2013–9.
28. Feliu J, Salud A, Safont MJ, Garcia-Giron C, Aparicio J, Vera R, et al. First-line
bevacizumab and capecitabine-oxaliplatin in elderly patients with mCRC:
GEMCAD phase II BECOX study. Br J Cancer. 2014;111:241–8.
29. McKibbin T, Frei CR, Greene RE, Kwan P, Simon J, Koeller JM. Disparities in
the use of chemotherapy and monoclonal antibody therapy for elderly
Munemoto et al. BMC Cancer  (2015) 15:786 Page 9 of 10
advanced colorectal cancer patients in the community oncology setting.
Oncologist. 2008;13:876–85.
30. Khattak MA, Townsend AR, Beeke C, Karapetis CS, Luke C, Padbury R, et al.
Impact of age on choice of chemotherapy and outcome in advanced
colorectal cancer. Eur J Cancer. 2012;48:1293–8.
31. Sorbye H, Pfeiffer P, Cavalli-Bjorkman N, Qvortrup C, Holsen MH, Wentzel-
Larsen T, et al. Clinical trial enrollment, patient characteristics, and survival
differences in prospectively registered metastatic colorectal cancer patients.
Cancer. 2009;115:4679–87.
32. Oba K, Matsuoka M, Satoh T, Muro K, Oriuchi N, Sakamoto J, et al.
Multicentre phase II study of XELOX with bevacizumab in late-stage elderly
patients with unresectable advanced/recurrent colorectal cancer: an ASCA
study. Jpn J Clin Oncol. 2011;41:134–8.
33. Hochster HS, Hart LL, Ramanathan RK, Childs BH, Hainsworth JD, Cohn AL,
et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with
or without bevacizumab as first-line treatment of metastatic colorectal
cancer: results of the TREE Study. J Clin Oncol. 2008;26:3523–9.
34. Doi T, Boku N, Kato K, Komatsu Y, Yamaguchi K, Muro K, et al. Phase I/II
study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line
therapy in Japanese patients with metastatic colorectal cancer. Jpn J Clin
Oncol. 2010;40:913–20.
35. Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, et al. Phase III
trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan
(FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and
irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer:
the Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007;25:1670–6.
36. Haller DG, Cassidy J, Clarke SJ, Cunningham D, Van Cutsem E, Hoff PM, et al.
Potential regional differences for the tolerability profiles of fluoropyrimidines.
J Clin Oncol. 2008;26:2118–23.
37. Folprecht G, Cunningham D, Ross P, Glimelius B, Di Costanzo F, Wils J, et al.
Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with
metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol.
2004;15:1330–8.
38. Lieu CH, Renfro LA, de Gramont A, Meyers JP, Maughan TS, Seymour MT, et al.
Association of age with survival in patients with metastatic colorectal cancer:
analysis from the ARCAD Clinical Trials Program. J Clin Oncol. 2014;32:2975–84.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Munemoto et al. BMC Cancer  (2015) 15:786 Page 10 of 10
